Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS There is no consensus on the best way to integrate biomarkers into inflammatory bowel disease (IBD) research and clinical practice. The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) aimed to outline biomarker definitions, categories, and operating properties required for their use in registration trials and clinical practice. Using fecal calprotectin as an example, we provide a framework for biomarker development and validation in patients with IBD. METHODS We reviewed international society guidelines, regulatory agency guidance documents, and standardized reporting guidelines for biomarkers, in combination with publications on fecal calprotectin levels in patients with IBD. We assessed the validity of fecal calprotectin to serve as a surrogate biomarker of IBD activity and outlined a framework for further validation and development of biomarkers. RESULTS No endpoints have been fully validated as surrogates of risk of disease complications-mucosal healing is the most valid endpoint used to determine risk of disease complications. Fecal level of calprotectin has not been validated as a biomarker for IBD activity, due to lack of technical and clinical reliability, assessment of performance when used as a replacement for endoscopy, and assessment of responsiveness to changes in disease states. The level of fecal calprotectin can be used only as a prognostic factor for disease recurrence in patients in remission following medical or surgical treatment. CONCLUSIONS We reviewed guidelines, regulatory documents, and publications to identify properties required for development of biomarkers of IBD activity and areas in need of clarification from regulatory agencies and societies. We propose a path forward for research of biomarkers for IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2015) · BMJ · doi:10.1136/bmj.h5527 · Cited by 3,660
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Self-citationHarbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx009 · Cited by 1,180
Self-citationApplication of biomarkers in the development of drugs intended for the treatment of osteoarthritis
Kraus, V. B., Burnett, B., Coindreau, J., Cottrell, S., Eyre, D., Gendreau, M., Gardiner, J., Garnero, P., Hardin, J., Henrotin, Y., et al. (2011) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.08.019 · Cited by 328
Fraser, C. G. (2012) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2011.733 · Cited by 286
Endoscopic monitoring of Crohn's disease treatment: A prospective, randomized clinical trial
Landi, B., Anh, T. N., Cortot, A., Soule, J. C., Rene, E., Gendre, J. P., Bories, P., See, A., Metman, E. H., Florent, C., et al. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91725-j · Cited by 261
Self-citation
Cited by
Positioning and usefulness of biomarkers in inflammatory bowel disease
Sakurai, T., & Saruta, M. (2023) · Digestion · doi:10.1159/000527846 · Cited by 156
Serum biomarkers confirming stable remission in inflammatory bowel disease
Kessel, C., Lavric, M., Weinhage, T., Brueckner, M., de Roock, S., Däbritz, J., Weber, J., Vastert, S. J., & Foell, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-86251-w · Cited by 54
Giachero, F., Jenke, A., & Zilbauer, M. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1945442 · Cited by 7
Metadata
- Authors
- Dulai, P. S., Peyrin-Biroulet, L., Danese, S., Sands, B. E., Dignass, A., Turner, D., Mantzaris, G., Schölmerich, J., Mary, J.-Y., Reinisch, W., & Sandborn, W. J.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 157
- Issue
- 4
- Pages
- 1032-1043.e1
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2949271110
- Cited by
- 58
- References
- 9
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. https://app.cochat.ai/papers/10.1053/j.gastro.2019.06.018
- The paper
- Dulai, P. S., Peyrin-Biroulet, L., Danese, S., Sands, B. E., Dignass, A., Turner, D., Mantzaris, G., Schölmerich, J., Mary, J.-Y., Reinisch, W., & Sandborn, W. J. (2019). Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.06.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.